Regeneron’s Dupixent drug could serve as the next big catalyst for shares of the pharmaceutical company, according to Jefferies.
You are here: Home / Jefferies says Regeneron’s Dupixent drug could drive shares 15% higher
Market News and Views
Regeneron’s Dupixent drug could serve as the next big catalyst for shares of the pharmaceutical company, according to Jefferies.